TRV GP VI, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001990716

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024

Q2 2026 · 4 positions · Total reported value $232.28M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 25.0% · 1 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, TRV GP VI, LLC disclosed 4 equity positions with a combined reported value of $232.28M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were SEPN ($141.05M), SPTX ($44.77M), RAPP ($40.39M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, TRV GP VI, LLC opened 1 new positions, trimmed 0 and fully exited 0, a turnover rate of 25.0% of positions. The portfolio's overlap with the prior quarter was 75% of names.

The largest new positions opened in Q2 2026 were SPTX ($44.77M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • SPTX SEAPORT THERAPEUTICS INC · $44.77M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest TRV GP VI, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-30 Award Rapport Therapeutics, Inc. 1,190,476 $21.00 SEC filing
2026-10-30 Award Rapport Therapeutics, Inc. 238,095 $21.00 SEC filing
2026-08-12 Sell Septerna, Inc. 141 $51.08 SEC filing
2026-08-12 Sell Septerna, Inc. 147,059 $50.27 SEC filing
2026-05-26 Sell Rapport Therapeutics, Inc. 18,572 $40.05 SEC filing
2026-05-11 Sell Rapport Therapeutics, Inc. 133,618 $40.24 SEC filing
2026-05-08 Sell Rapport Therapeutics, Inc. 5,018 $40.31 SEC filing
2026-05-07 Sell Rapport Therapeutics, Inc. 271,495 $40.12 SEC filing

All insider transactions →

Fund Profile

TRV GP VI files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 4 positions worth $232.28M in total. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).

Portfolio Structure

  • 4 positions · $232.28M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: SEPN (SEPTERNA INC) at 60.7%
  • Average position size: $58.07M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new
  • 3 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautious stance with a focus on health care sector investments, indicating a belief in the stability and potential growth of this sector. 2. Key Moves: - Added: SEAPORT THERAPEUTICS INC (SPTX) as a new holding, signaling a new interest in biotechnology or pharmaceuticals. - No Change: Continued to hold existing positions in SEPTERNA INC (SEPN), RAPPORT THERAPEUTICS INC (RAPP), and TANGO THERAPEUTICS INC (TNGX) without any changes in share count or weight. - No Reductions: There were no reported reductions in holdings. 3. Portfolio Structure: - Passive vs. Active: The portfolio seems to lean towards a passive strategy, as it maintains existing holdings without significant changes and adds a new holding without a clear directional shift. - Sector Bias: The fund has a strong bias towards the health care sector, reflecting a focus on biotechnology and pharmaceuticals. - Risk Appetite: The risk appetite is moderate, as the fund maintains a diversified portfolio within the health care sector and does not exhibit aggressive additions or deletions. 4. Per-Holding One-Liner: - SEPN: SEPTERNA INC - Develops and commercializes novel therapies for chronic diseases. - SPTX: SEAPORT THERAPEUTICS INC - Engages in the research and development of novel therapies in the fields of oncology and inflammation. - RAPP: RAPPORT THERAPEUTICS INC - Focuses on the development of therapies for rare genetic diseases. - TNGX: TANGO THERAPEUTICS INC - Specializes in the development of novel treatments for neurological and psychiatric disorders. - Unverified: None. 5. One-Sentence Style Summary: The TRV GP VI, LLC fund maintained its health care sector focus, adding a new biotechnology holding, while showing a preference for passive management and moderate risk tolerance.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 4.21M $141.05M 60.73%
60.73%
Hold
2 2.06M $44.77M 19.27%
19.27%
New
3 969.22K $40.39M 17.39%
Form 4 · 2 →
17.39%
Hold
4 194.17K $6.07M 2.61%
2.61%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 100% R 75% F1 86% (modelled on 2026-Q1; 3/10 hit)

Historical Backtest (5 quarters)

Avg precision 95% · recall 95% · F1 94% · avg rank error 1.0 · Top-10 turnover 4%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2025-Q2 100% 100% 100% SEPN · RAPP · CRGX · TNGX SEPN · RAPP · CRGX · TNGX
2025-Q3 75% 100% 86% SEPN · RAPP · CRGX · TNGX SEPN · RAPP · TNGX
2025-Q4 100% 100% 100% SEPN · RAPP · TNGX SEPN · RAPP · TNGX
2026-Q1 100% 100% 100% SEPN · RAPP · TNGX SEPN · RAPP · TNGX
2026-Q2 ★ 100% 75% 86% SEPN · RAPP · TNGX SEPN · SPTX · RAPP · TNGX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did TRV GP VI, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, TRV GP VI, LLC reported 4 equity positions worth $232.28M in aggregate; its largest disclosed positions were SEPN ($141.05M), SPTX ($44.77M), RAPP ($40.39M).

How large is TRV GP VI, LLC's portfolio?

TRV GP VI, LLC reported $232.28M of long equity holdings across 4 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is TRV GP VI, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/trv-gp-vi/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →